Investors

The financing received by Presidio Pharmaceuticals from its investors has opened the door to new breakthroughs and possibilities. Dr. Omar K. Haffar, President and CEO, notes, "As we advance our programs into clinical development, Presidio is in a strong position to both improve upon present treatments for patients with anti-viral infections and create substantial value for our investors by leveraging our technology and management expertise."

For information on ways your organization can participate in future rounds of financing, contact a Presidio representative.

Founding Investors

The original investors in Presidio Pharmaceuticals include Sagamore Bioventures, a life science venture fund headquartered in San Francisco, CA, as well as the George Rathmann Family Fund and Peninsula Overview Partners.

Additional Investors

Baker Brothers Investments. Baker Brothers Investments is a family of long-term investment funds managed by Baker Bros. Advisors university endowments and foundations that are focused on publicly traded life sciences companies.

Bay City Capital. Bay City Capital is a life sciences venture capital firm investing in opportunities across the various life sciences sectors in companies at all stages of development. Established in 1997, Bay City Capital has managed six venture funds representing $1.4 billion in capital commitments. The firm has invested in over 65 companies to date and is actively seeking new investment opportunities.

New Leaf Venture Partners. NLV Partners is a life science-dedicated venture capital firm with offices in Menlo Park and New York. Founded by an experienced team of venture capitalists with deep healthcare industry experience, NLV Partners invests primarily in companies focused on clinical-stage biopharmaceutical products, early-stage medical devices and molecular diagnostics. NLV Partners manages over $1.3 billion of assets, including NLV-I, NLV-II and the healthcare technology portfolio of Sprout Group.

Nexus Medical Partners. Nexus Medical Partners is a private equity firm specializing in making private equity investments in and providing strategic assistance to medical technology and selected life science companies. Each of the Nexus Principals averages twenty years in the business. In addition to being experienced equity investors, the backgrounds of the Principals include successful careers in medical device and pharmaceutical line management of both established and emerging companies, medical industry business development, Wall Street analysis and legal practice.

Panorama Capital. The Panorama Capital team was spun out of JPMorgan Partners ("JPMP") in 2006 to create an independent venture firm that invests primarily in high-growth, development-stage life sciences and technology companies. Panorama Capital uses its team's extensive experience, track record and investment discipline to continue the successful life sciences and technology investment strategy executed during its tenure at JPMP.

Ventures West Management. Ventures West Capital Ltd., a private venture capital investment group, is one of Canada’s leading investors in seed and early stage technology companies. Since its founding in 1968, Ventures West has formed eight venture capital funds which total over $700 million and has invested in more than 150 companies. Ventures West has the people, the expertise, and the capital to help entrepreneurs develop emerging technology companies into market leaders.


	Investors The financing received by Presidio Pharmaceuticals from its investors has opened the door to new breakthroughs and possibilities. Dr. Omar K. Haffar, President and CEO, notes, "As we advance our programs into clinical development, Presidio is in a strong position to both improve upon present treatments for patients with anti-viral infections and create substantial value for our investors by leveraging our technology and management expertise." For information on ways your organization can participate in future rounds of financing, contact a Presidio representative. Founding Investors The original investors in Presidio Pharmaceuticals include Sagamore Bioventures, a life science venture fund headquartered in San Francisco, CA, as well as the George Rathmann Family Fund and Peninsula Overview Partners. Additional Investors Baker Brothers Investments. Baker Brothers Investments is a family of long-term investment funds managed by Baker Bros. Advisors university endowments and foundations that are focused on publicly traded life sciences companies. Bay City Capital. Bay City Capital is a life sciences venture capital firm investing in opportunities across the various life sciences sectors in companies at all stages of development. Established in 1997, Bay City Capital has managed six venture funds representing $1.4 billion in capital commitments. The firm has invested in over 65 companies to date and is actively seeking new investment opportunities. New Leaf Venture Partners. NLV Partners is a life science-dedicated venture capital firm with offices in Menlo Park and New York. Founded by an experienced team of venture capitalists with deep healthcare industry experience, NLV Partners invests primarily in companies focused on clinical-stage biopharmaceutical products, early-stage medical devices and molecular diagnostics. NLV Partners manages over $1.3 billion of assets, including NLV-I, NLV-II and the healthcare technology portfolio of Sprout Group. Nexus Medical Partners. Nexus Medical Partners is a private equity firm specializing in making private equity investments in and providing strategic assistance to medical technology and selected life science companies. Each of the Nexus Principals averages twenty years in the business. In addition to being experienced equity investors, the backgrounds of the Principals include successful careers in medical device and pharmaceutical line management of both established and emerging companies, medical industry business development, Wall Street analysis and legal practice. Panorama Capital. The Panorama Capital team was spun out of JPMorgan Partners ("JPMP") in 2006 to create an independent venture firm that invests primarily in high-growth, development-stage life sciences and technology companies. Panorama Capital uses its team's extensive experience, track record and investment discipline to continue the successful life sciences and technology investment strategy executed during its tenure at JPMP. Ventures West Management. Ventures West Capital Ltd., a private venture capital investment group, is one of Canada’s leading investors in seed and early stage technology companies. Since its founding in 1968, Ventures West has formed eight venture capital funds which total over $700 million and has invested in more than 150 companies. Ventures West has the people, the expertise, and the capital to help entrepreneurs develop emerging technology companies into market leaders. Presidio Pharmaceuticals, Inc.